JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB76157

Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y]

  • 20ul selling size
  • KO Validated
  • RabMAb
  • Recombinant
  • What is this?

0

(1 Review)

|

(8 Publications)

Knockout Tested Rabbit Recombinant Monoclonal Indoleamine 2, 3-dioxygenase antibody. Suitable for WB and reacts with Human samples. Cited in 8 publications.

View Alternative Names

IDO, INDO, IDO1, IDO-1

3 Images
Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (AB76157)
  • WB

Lab

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (AB76157)

Lanes 1 - 6 : Merged signal (red and green). Green - ab76157 observed at 40 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55 kDa.

ab76157 was shown to react with Indoleamine 2, 3-dioxygenase in treated wild-type A549 cells in Western blot with loss of signal observed in treated IDO1 knockout cell line ab266949 (IDO1 knockout cell lysate ab256948). Wild-type A549 and IDO1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab76157 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at a 1 in 2500 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (ab76157) at 1/2500 dilution

Lane 1:

Wild-type A549 Vehicle Control IFN gamma (0 ng/ml, 48 h) cell lysate at 20 µg

Lane 2:

Wild-type A549 Treated IFN gamma (25 ng/ml, 48 h) cell lysate at 20 µg

Lane 3:

IDO1 knockout A549 Vehicle Control IFN gamma (0 ng/ml, 48 h) cell lysate at 20 µg

Lane 4:

IDO1 knockout A549 Treated IFN gamma (25 ng/ml, 48 h) cell lysate at 20 µg

Lane 5:

SK-OV-3 cell lysate at 20 µg

Lane 6:

MCF7 cell lysate at 20 µg

Secondary

Lanes 1 - 6:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/20000 dilution

Lanes 1 - 6:

Western blot - Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-680rd-preadsorbed-ab216776'>ab216776</a>) at 1/20000 dilution

Predicted band size: 45 kDa

Observed band size: 40 kDa,55 kDa

false

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (AB76157)
  • WB

Unknown

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (AB76157)

The expression of Indoleamine 2, 3-dioxygenase can be upregulated by IFN-gamma (PMID : 29685162). We are unsure how to define the extra bands.

All lanes:

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (ab76157) at 1/1000 dilution

Lane 1:

HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate at 15 µg

Lane 2:

HeLa (Human cervix adenocarcinoma epithelial cell) treated with 10ng/ml IFN-gamma for 24 hours whole cell lysate at 15 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 45 kDa

false

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (AB76157)
  • WB

Lab

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (AB76157)

Western blot : Anti-IDO1 antibody [EPR1230Y] (ab76157) staining at 1/2500 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab76157 was shown to bind specifically to IDO1. A band was observed at 42/56 kDa in treated wild-type A549 cell lysates with no signal observed at this size in IDO1 knockout cell line. To generate this image, wild-type and IDO1 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] (ab76157) at 1/2500 dilution

Lane 1:

Wild-type A549 Treated IFN gamma (25 ng/mL, 48 h) ab281500 cell lysate at 20 µg

Lane 2:

Wild-type A549 Vehicle Control IFN gamma (0 ng/mL, 48 h) ab255554 cell lysate at 20 µg

Lane 3:

IDO1 knockout A549 Treated IFN gamma (25 ng/mL, 48 h) ab281489 cell lysate at 20 µg

Lane 4:

IDO1 knockout A549 Vehicle Control IFN gamma (0 ng/mL, 48 h) ab263515 cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Predicted band size: 45 kDa

Observed band size: 42 kDa,56 kDa

false

  • Carrier free

    Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] - Low endotoxin, Azide free

  • Carrier free

    Anti-Indoleamine 2, 3-dioxygenase antibody [EPR1230Y] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR1230Y

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "10 µg/mL", "ICCIF-species-notes": "<p></p>" }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Indoleamine 2 3-dioxygenase (IDO) also known as IDO1 is an enzyme involved in the catabolism of tryptophan to kynurenine. It weighs approximately 45 kDa and it is an important target in immunoregulatory processes. IDO is highly expressed in antigen-presenting cells such as dendritic cells and macrophages as well as in various tumor cells where it helps modulate immune responses. This enzyme can also be measured by using assays like IDO ELISA.
Biological function summary

IDO plays a role in immune response regulation by degrading tryptophan an essential amino acid needed for T-cell proliferation. The depletion of tryptophan and the accumulation of its metabolites such as kynurenine cause immunosuppressive effects within the tissue microenvironment. While IDO functions mostly as a standalone enzyme its activity influences the cellular surroundings by altering the balance of local immune reactions.

Pathways

IDO integrates into the tryptophan metabolism pathway and is important in the kynurenine pathway. Through this pathway it maintains immune homeostasis and cell defense mechanisms. Proteins like kynureninase and kynurenine 3-monooxygenase also participate in the same metabolic processes which further extend the effects of tryptophan metabolism on immune cell behavior.

IDO is linked with cancer and chronic inflammatory conditions. In cancer elevated IDO expression suppresses anti-tumor immunity aiding tumor cells to evade immune surveillance. It also plays a role in autoimmune disorders by regulating excessive immune activity. During cancer progression IDO often works in conjunction with immune checkpoint proteins like PD-L1 which further enhances its immunosuppressive capabilities within the tumor microenvironment.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway (PubMed : 17671174, PubMed : 18026683). Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses (PubMed : 25691885). Tryptophan shortage inhibits T lymphocytes division and accumulation of tryptophan catabolites induces T-cell apoptosis and differentiation of regulatory T-cells (PubMed : 25691885). Acts as a suppressor of anti-tumor immunity (PubMed : 14502282, PubMed : 23103127, PubMed : 25157255, PubMed : 25691885). Limits the growth of intracellular pathogens by depriving tryptophan (PubMed : 25691885). Protects the fetus from maternal immune rejection (PubMed : 25691885).
See full target information IDO1

Publications (8)

Recent publications for all applications. Explore the full list and refine your search

Communications biology 7:669 PubMed38822095

2024

Decidual natural killer cells dysfunction is caused by IDO downregulation in dMDSCs with Toxoplasma gondii infection.

Applications

Unspecified application

Species

Unspecified reactive species

Yu Wang,Xiaoyue Zhao,Zhidan Li,Wenxiao Wang,Yuzhu Jiang,Haixia Zhang,Xianbing Liu,Yushan Ren,Xiaoyan Xu,Xuemei Hu

Cell 172:423-438.e25 PubMed29249360

2017

Intrinsic Immunity Shapes Viral Resistance of Stem Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Xianfang Wu,Viet Loan Dao Thi,Yumin Huang,Eva Billerbeck,Debjani Saha,Hans-Heinrich Hoffmann,Yaomei Wang,Luis A Vale Silva,Stephanie Sarbanes,Tony Sun,Linda Andrus,Yingpu Yu,Corrine Quirk,Melody Li,Margaret R MacDonald,William M Schneider,Xiuli An,Brad R Rosenberg,Charles M Rice

SLAS discovery : advancing life sciences R & D 23:34-46 PubMed28957646

2017

A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1.

Applications

Unspecified application

Species

Unspecified reactive species

Dean E McNulty,William G Bonnette,Hongwei Qi,Liping Wang,Thau F Ho,Anna Waszkiewicz,Lorena A Kallal,Raman P Nagarajan,Melissa Stern,Amy M Quinn,Caretha L Creasy,Dai-Shi Su,Alan P Graves,Roland S Annan,Sharon M Sweitzer,Marc A Holbert

The British journal of dermatology 177:809-817 PubMed28132413

2017

Immunotolerant indoleamine-2,3-dioxygenase is increased in condyloma acuminata.

Applications

Unspecified application

Species

Unspecified reactive species

Z Xie,M Zhang,W Xiong,H Y Wan,X C Zhao,T Xie,H Lei,Z C Lin,D S Luo,X L Liang,Y H Chen

Stem cell research & therapy 8:101 PubMed28446226

2017

Xenotransplantation of interferon-gamma-pretreated clumps of a human mesenchymal stem cell/extracellular matrix complex induces mouse calvarial bone regeneration.

Applications

WB, ICC/IF

Species

Human, Human

Kei Takeshita,Souta Motoike,Mikihito Kajiya,Nao Komatsu,Manabu Takewaki,Kazuhisa Ouhara,Tomoyuki Iwata,Katsuhiro Takeda,Noriyoshi Mizuno,Tsuyoshi Fujita,Hidemi Kurihara

Oncotarget 7:57606-57617 PubMed27613847

2016

Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation.

Applications

Unspecified application

Species

Unspecified reactive species

Wejdan A Aldajani,Fabián Salazar,Herb F Sewell,Alan Knox,Amir M Ghaemmaghami

Journal of infection and chemotherapy : official j 20:460-4 PubMed24855914

2014

Effect of Ureaplasma parvum co-incubation on Chlamydia trachomatis maturation in human epithelial HeLa cells treated with interferon-γ.

Applications

Unspecified application

Species

Human

Tomohiro Yamazaki,Junji Matsuo,Shinji Nakamura,Satoshi Oguri,Hiroyuki Yamaguchi

Blood 116:1755-60 PubMed20511543

2010

Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease.

Applications

Unspecified application

Species

Unspecified reactive species

Suk See De Ravin,Kol A Zarember,Debra Long-Priel,King C Chan,Stephen D Fox,John I Gallin,Douglas B Kuhns,Harry L Malech
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com